Thank you !

Access info about Drug Diversion Monitoring on your dashboard or bookmark under

(Your Products / Your Organization's Products)

We are currently researching Drug Diversion Monitoring.

Will you help us?

Take A Survey

Premium Reports
 Download Report Brief  Download Full Report    Zoom in charts

Preferences

   Bookmark

Related Series

Drug Diversion Monitoring 2021
|
2021

Related Segments

Related Products

Related Vendors

 End chart zoom
Drug Diversion Monitoring 2019 Drug Diversion Monitoring 2019
* A page refresh may be necessary to see the updated image

Drug Diversion Monitoring 2019
An Early Look at Emerging vs. Established Technology

author - Jackson Tate
Author
Jackson Tate
author - Paul Warburton
Author
Paul Warburton
 
August 20, 2019 | Read Time: 3  minutes

Current Time Inside Cache Tag Helper: 10/19/2021 3:07:33 AM and Model.reportId = 1570

Given the increased nationwide focus on the opioid epidemic, there has been a surge in demand for advanced drug diversion monitoring tools. Both established and emerging vendors have responded by developing new solutions that promise next-generation technology to comprehensively and proactively monitor dispensing behaviors. This report offers an early look at how far along these vendors are and what the customer experience is like so far. Despite increased interest, few customers feel they are having a true next-generation experience with their solution today.

Thank you !

Access info about Drug Diversion Monitoring on your dashboard or bookmark under

(Your Products / Your Organization's Products)

We are currently researching Drug Diversion Monitoring.

Will you help us?

Take A Survey

HtmlReportContent Current Time Inside Cache Tag Helper: 10/19/2021 3:07:33 AM and Model.reportId= 1570 and Model.HtmlReportContent_LastWriteTimeUtcInTicks=637534249881532210

Established Vendors

Omnicell Analytics: Most-Adopted Emerging Solution, but Many Hamstrung without EMR Integration

overall performanceOmnicell Analytics is the emerging solution with the most adoption (mostly from former Pandora Analytics clients). Similar to other customer bases, Omnicell Analytics customers with EMR integration report having more comprehensive visibility into dispensing behavior. However, because EMR integration costs extra, a significant number of customers do not have it, are thus unable to drive expected outcomes, and resort to manual processes that result in a higher number of false positives. Omnicell’s Pandora customers tend to be more satisfied than Omnicell Analytics customers—though the older system is more manual and less advanced, it still functions as expected.

impact of emr integration

EMR Integration Key to Success

EMR integration dramatically improves customer success with drug diversion monitoring solutions. It enables analytics tools to compare drug-use data from the eMAR, not just pharmacy systems, closing the loop on the full medication administration process, improving accuracy, and creating a more complete picture for investigation.


Most Medacist RxAuditor Customers Dissatisfied with Manual Investigation Workflows

investigation workflow ratingMedacist RxAuditor clients report dated technology and clunky investigation workflows as key issues hindering effective drug diversion monitoring. By far the largest vendor in the market, Medacist offers several tools intended to provide advanced capabilities, but very few respondents report having or using these tools. Most say their system relies solely on dispensing data from cabinets and carousels and generates lengthy reports that flag abnormal behaviors. While these reports include a wealth of information, respondents are frustrated at having to spend significant time manually weeding out false positives and identifying true diversion. Due to these challenges, 5 of the 16 interviewed RxAuditor customers report the solution is not part of their long-term plans and are turning to other vendors for technology that better supports investigation. Medacist is beta testing a new solution, RxAuditor Investigate, to address product gaps.


Emerging Vendors


Kit Check (Limited Data) Shows Early Signs of Consistent Next-Gen Experience and Improved Accuracy

quality of training vs accurate detectionKit Check has expanded on their existing kit/tray management customer base with their new drug diversion monitoring solution, Bluesight for Controlled Substances; to date, fewer than 20 organizations are live on the solution. Early data on Kit Check suggests customers are having a strong experience overall. Respondents report Kit Check sets clear expectations and provides rigorous training, helping them overcome the learning curve involved in setting up the right criteria and interfaces to optimize system accuracy and limit false positives. Due to their small customer base, Kit Check also nimbly responds to customer development requests. Respondents report they have EMR and other types of integration, giving them a complete picture of dispensing behavior for investigation. The system is also easy to use and includes tools that help users document investigation findings.

Emerging Solutions Still Vying for Purchase Energy

Other emerging options are also getting consideration, though adoption to date is limited. BD’s new offering—HealthSight Diversion Management—has potential for high adoption given BD’s existing pharmacy customer base. Without existing pharmacy customers, new third-party entrants HelioMetrics, Invistics, and Protenus (each with a handful of live customers) face bigger adoption hurdles since most pharmacies are looking to consolidate to fewer vendors
to improve integration.


Drug Diversion Monitoring Vendor Scope

drug diversion monitoring vendor scope
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.